Sustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma.
Chengxin ZhouFengyang LeiJyoti SharmaPui-Chuen HuiNatalie WolkowClaes H DohlmanDemetrios George VavvasJames ChodoshEleftherios I PaschalisPublished in: Pharmaceutics (2023)
Concomitant inhibition of TNF-α and VEGF prevents corneal neovascularization and ameliorates subsequent irreversible damage to the retina and optic nerve after severe ocular injury. A single subconjunctival administration of this therapy, using a biodegradable, slow-release thermosensitive DDS, achieved the sustained elution of therapeutic levels of antibodies to all ocular tissues for 3 months. This therapeutic approach has the potential to dramatically improve the outcomes of severe ocular injuries in patients and improve the therapeutic outcomes in patients with retinal vascular diseases.
Keyphrases
- optic nerve
- optical coherence tomography
- vascular endothelial growth factor
- diabetic retinopathy
- early onset
- end stage renal disease
- rheumatoid arthritis
- mouse model
- endothelial cells
- ejection fraction
- gene expression
- drug delivery
- chronic kidney disease
- newly diagnosed
- oxidative stress
- prognostic factors
- drug induced
- stem cells
- risk assessment
- human health
- climate change
- patient reported outcomes